

1 **Comorbidity Profiles of Posttraumatic Stress Disorder Across the Medical Phenome.**

2 Emily M. Hicks¹, Maria Niarchou², Slavina Goleva², Dia Kabir³, Julia Ciarcia⁴, PTSD & Trauma EHR Working
3 Group, Jordan W. Smoller^{3,5,6}, Lea K. Davis², Caroline M. Nievergelt^{7,8,9}, Karestan C. Koenen^{5,6,10}, Laura M.
4 Huckins*⁴, Karmel W. Choi*³

5

6 Affiliations:

7 [1] Pamela Sklar Division of Psychiatric Genetics, Icahn School of Medicine at Mount Sinai, New York, NY,
8 USA

9 [2] Vanderbilt University Medical Center, Vanderbilt Genetics Institute, Nashville, TN, USA

10 [3] Massachusetts General Hospital, Department of Psychiatry, Boston, MA, USA

11 [4] Department of Psychiatry, Division of Molecular Psychiatry, Yale University School of Medicine, New
12 Haven, CT, USA

13 [5] Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Research, Cambridge, MA

14 [6] Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Boston, MA

15 [7] University of California San Diego, Department of Psychiatry, La Jolla, CA

16 [8] Veterans Affairs San Diego Healthcare System, Center of Excellence for Stress and Mental Health, San
17 Diego, CA

18 [9] Veterans Affairs San Diego Healthcare System, Research Service, San Diego, CA

19 [10] Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, US

20

21

22 **Abstract**

23 **Background:** Prior epidemiological research has linked PTSD with specific physical health problems, but the
24 comprehensive landscape of medical conditions associated with PTSD remains uncharacterized. Electronic health
25 records (EHR) provide an opportunity to overcome prior clinical knowledge gaps and uncover associations with
26 biological relevance that potentially vary by sex.

27 **Methods:** PTSD was defined among biobank participants (total N=123,365) in a major healthcare system using
28 two ICD code-based definitions: broad (1+ PTSD or acute stress codes versus 0; $N_{\text{Case}}=14,899$) and narrow (2+
29 PTSD codes versus 0; $N_{\text{Case}}=3,026$). Using a phenome-wide association (PheWAS) design, we tested associations
30 between each PTSD definition and all prevalent disease umbrella categories, i.e., phecodes. We also conducted
31 sex-stratified PheWAS analyses including a sex-by-diagnosis interaction term in each logistic regression.

32 **Results:** A substantial number of phecodes were significantly associated with PTSD_{Narrow} (61%) and PTSD_{Broad}
33 (83%). While top associations were shared between the two definitions, PTSD_{Broad} captured 334 additional
34 phecodes not significantly associated with PTSD_{Narrow} and exhibited a wider range of significantly associated
35 phecodes across various categories, including respiratory, genitourinary, and circulatory conditions. Sex
36 differences were observed, in that PTSD_{Broad} was more strongly associated with osteoporosis, respiratory failure,
37 hemorrhage, and pulmonary heart disease among male patients, and with urinary tract infection, acute pharyngitis,
38 respiratory infections, and overweight among female patients. **Conclusions:** This study provides valuable
39 insights into a diverse range of comorbidities associated with PTSD, including both known and novel
40 associations, while highlighting the influence of sex differences and the impact of defining PTSD using EHR.

41

42

43

44

45

46

47

48

49 Introduction

50

51 Post-traumatic stress disorder (PTSD) occurs following highly stressful and/or traumatic events. Not only
52 does PTSD impair occupational performance, social relationships, and overall quality of life, it frequently
53 presents with comorbidities¹, defined broadly here as co-occurring health conditions. Common PTSD
54 comorbidities include psychiatric conditions such as depression and anxiety^{2,3}, and physical health problems
55 including cardiovascular disease⁴ and gastrointestinal conditions⁵. However, the comprehensive landscape of
56 PTSD comorbidities, particularly in healthcare contexts, has remained incompletely characterized⁶. This limits
57 clinical insights into complex needs of patients with PTSD (i.e., what other medical concerns to consider in
58 formulating a treatment plan) as well as empirical insights into medical conditions that may serve as risk factors
59 for PTSD and/or share underlying biological mechanisms⁷.

60 Electronic health records (EHR) provide a unique opportunity to uncover such associations with clinical
61 and potential biological relevance. EHR offer large samples and longitudinal data including all diagnoses that a
62 patient receives while active in that healthcare system, recorded using standardized diagnostic billing codes that
63 can be examined in tandem across multiple systems. Such codes can be used in different ways to identify post-
64 traumatic psychopathology⁸. While PTSD is designated by specific billing codes, providers may choose to assign
65 a broader code to reflect diagnostic uncertainty, higher likelihood of insurance coverage, stigma reduction, or
66 other factors, meaning that some PTSD cases may be missed when simply focusing on a narrow set of codes. In
67 addition to identifying specific codes, we can also consider how frequently they are assigned to an individual.
68 Accordingly, a broader definition might include a single diagnosis of any stress-related disorder versus a narrow
69 definition requiring multiple diagnoses of PTSD specifically. This has implications for epidemiologic⁹ and
70 genomic studies that leverage these definitions to identify PTSD cases and controls from EHR (for example,
71 GWAS^{10,11}), where a broader definition can inclusively capture more cases, enhancing discovery power, but may
72 also introduce non-specific associations¹². How we identify individuals with post-traumatic psychopathology
73 using EHR, i.e., with more inclusive versus narrow definitions, may impact our ability to resolve relevant
74 comorbidities, and the translatability of resulting genetic findings.

75 In addition to a need to resolve wide-ranging PTSD comorbidities, important sex differences may also
76 exist in such comorbidities. The burden of PTSD varies by sex^{3,13}, with rates of lifetime PTSD about twice as high
77 in females compared to males¹⁴. Understanding why PTSD prevalence differs by sex is complex; rather than
78 simply capturing intrinsic biological sex differences in risk, differences may reflect gendered environments
79 including trauma exposure (e.g., interpersonal violence)¹⁵⁻¹⁹ or available supports. Male, female, and intersex
80 patients may also have different experiences within healthcare systems, including where and how care is received,
81 access to care, and their diagnostic journey for PTSD. As such, the medical conditions that co-occur with PTSD
82 may also differ²⁰.

83 In this multi-site study, we sought to investigate the relationships between different PTSD phenotypes and
84 the medical phenome using data from 123,365 patients enrolled in biobanks across three major EHR-based
85 healthcare systems. Our objectives were to comprehensively identify medical comorbidities associated with
86 PTSD, and to examine whether these associations varied based on broad versus narrow definitions, and by sex.
87 Finally, we explored how each PTSD definition relates to polygenic signals to understand implications for
88 downstream genomic and clinical research.

89

90

91 **Methods**

92 **Samples**

93 Our study includes 123,365 biobank research participants with available genetic and longitudinal EHR
94 data²¹ from three major health systems—Vanderbilt University Medical Center (VUMC, n=73,488), Mount Sinai
95 (MSSM, n=31,704), and Mass General Brigham (MGB, n=29,885). Sample characteristics (**Table 1**) and
96 phenotype category codes (phecodes) frequencies (**Supplementary Table 1**) and study information
97 (**Supplementary Material 1**) for each site are provided.

98

99 **PTSD exposures**

100 PTSD case-control phenotypes were defined using two ICD code-based definitions. Individuals who met broad
101 PTSD criteria (PTSD_{Broad}) had ≥ 1 PTSD (309.81, F43.1, F43.10, F43.11, F43.12) or stress-related disorder code
102 (310.2, F07.81, 309, 309.1, 309.2, 309.21, 309.22, 309.23, 309.24, 309.28, 309.29, 309.3, 309.4, 309.82, 309.83,
103 309.89, 309.9, F43, F43.0, F43.2, F43.20, F43.21, F43.22, F43.23, F43.24, F43.25, F43.29, F43.8, F43.9), while
104 controls had no such code; individuals who met narrow PTSD criteria (PTSD_{Narrow}) had ≥ 2 PTSD codes only,
105 while controls had no codes for PTSD, other stress-related disorders, or post-concussive injury.

106

107 **Main PheWAS analyses**

108 We used a phenome-wide association (PheWAS) design to test logistic regression associations between
109 PTSD_{Narrow} or PTSD_{Broad} with all phecodes as previously defined²². Cases for each outcome phecode had ≥ 2 ICD
110 codes belonging to that phecode category, while controls had 0 codes in that category (individuals with only one
111 code were excluded). We excluded outcome phecodes derived from the same ICD codes used to define
112 PTSD_{Narrow} (phecode 300.9 (“Posttraumatic Stress Disorder”)) and PTSD_{Broad} (phecodes 300.8 (“Acute Reaction to
113 Stress”), 304 (“Adjustment Reaction”), and 300.9 (“Posttraumatic Stress Disorder”)) to eliminate circularity of
114 exposure and outcome. We adjusted the models for age, genetically inferred ancestry (European [EUR], African
115 [AA], Americas [AMR], East Asian [EAS], where available at each site), sex, and top 5 PCs to adjust for residual
116 differences. As a sensitivity analysis, each site also tested PheWAS models in which genetic PCs were not

117 included as a covariate. We applied a Bonferroni threshold to establish significance, correcting for 1324 tests
118 ($p_{\text{BONF}} < 3.7 \times 10^{-5}$; $\text{PTSD}_{\text{Narrow}}$) and 1367 tests ($p_{\text{BONF}} < 3.8 \times 10^{-5}$; $\text{PTSD}_{\text{Broad}}$). We assessed enrichment of phecode
119 categories of associations reaching Bonferroni significance, and the top 25% of associations, using a binomial
120 test.

121 For all phecodes appearing in ≥ 2 sites in the analysis (1649 phecodes were available for ≥ 2 sites; 765
122 were available for all three sites), we meta-analyzed across sites using fixed-effects in the *PheWAS* R package²³.
123 To assess heterogeneity, we calculated I^2 statistics in METAL²⁴ to identify associations that differed in effect sizes
124 between health systems. Phecodes with $I^2 < 0.1$ were considered significantly heterogeneous. While we observed
125 significant heterogeneity among effect size estimates across sites for both $\text{PTSD}_{\text{Narrow}}$ and $\text{PTSD}_{\text{Broad}}$ PheWAS,
126 directions of effect and top associations across sites remained largely uniform (**Supplementary Table 2**).

127

128 **Sex-stratified and sex-interaction PheWAS Analyses**

129 We conducted sex-stratified PheWAS analyses ($n=13,228$ female, $n=11,614$ male), adjusting for age,
130 ancestry, and top 5 PCs. Patient sex was categorized as follows: MGB: sex assigned at birth, VUMC: sex assigned
131 at birth, Mount Sinai: karyotypic sex; a small number of intersex individuals and individuals who declined to state
132 their sex were excluded from this analysis. For all Bonferroni-significant phecodes from the full or sex-stratified
133 analyses, we conducted an analysis including a sex-by-diagnosis interaction term in each logistic regression.
134 Interaction effect sizes were meta-analyzed using an inverse-variance weighted model using a “STDERR” scheme
135 with METAL software²⁴.

136

137 **Polygenic score analyses**

138 We assessed genetic correlates of PTSD definitions in individuals of European (EUR) and African
139 ancestries (AA) based on PTSD polygenic scores (PGS). We calculated PGS inferring SNPs weights from
140 European PGC-PTSD GWAS summary statistics (discovery $n=174,659$)²⁵ as implemented in PRS-CSx²⁶ and
141 summing allele counts weights. For each available ancestry group within each health system, we normalized the
142 PGS and tested their association with $\text{PTSD}_{\text{Narrow}}$ or $\text{PTSD}_{\text{Broad}}$ using logistic regression, including sex, age, and

143 within-ancestry genotype-derived principal components (PCs). We estimated phenotypic variance explained by
144 PTSD scores using Nagelkerke's R^2 ²⁷. We meta-analyzed PGS associations with fixed effects using the metafor
145 package²⁸.

146 **Results**

147 **Sample**

148 To examine phenome-wide comorbidities of PTSD, we conducted analyses included 123,365 patients
149 (3,026 and 14,899 meeting the PTSD_{Narrow} versus PTSD_{Broad} definitions, respectively) across three major
150 healthcare systems: VUMC, MGB and MSSM (**Table 1**). Prevalence of PTSD_{Narrow} and PTSD_{Broad} at MGB
151 (4.32% and 22.14%, respectively) were higher than the other two sites (VUMC: 1.9% and 9.37%, MSSM: 1.69%
152 and 6.98%).

153

154 **Narrowly and broadly defined PTSD definitions have wide-ranging correlates across the medical phenome**

155 807 of 1324 (61%) phecodes were significantly associated with PTSD_{Narrow} and 1136 or 1367 (83%) with
156 PTSD_{Broad} ($p_{\text{Bonf}} < 3.8 \times 10^{-5}$, 3.7×10^{-5} , respectively; full summary statistics: **Supplementary Table 2**). Top
157 PTSD_{Narrow} associations included psychiatric and pain-related phecodes, whereas top PTSD_{Broad} associations
158 included psychiatric and pain-related phecodes as well as respiratory, genitourinary, and circulatory phecodes
159 (**Figure 1**). Phecode associations with PTSD were primarily positive: we observed an increased risk of each of
160 these phecodes among individuals with PTSD. Only a very small minority of phecodes was negatively associated
161 with PTSD, including regional enteritis (Crohn's) ($p=0.019$, $OR=0.77$; $p=0.0061$, $OR=0.86$ for PTSD_{Narrow} and
162 PTSD_{Broad}, respectively) and prostate cancer ($p=0.014$, $OR=0.61$; $p=0.022$, $OR=0.87$) (**Supplementary Table 2**).
163 Notably, these negative directions of effect were consistent across all sites.

164

165 **Narrowly-defined PTSD shows strong associations with neuropsychiatric traits**

166 PTSD_{Narrow} was associated with over 85% of phecodes in the mental disorders category (**Supplementary**
167 **Table 3**). Among the top 25% of phecodes associated with PTSD_{Narrow}, 'mental disorders' and 'symptoms'
168 categories were significantly enriched after Bonferroni correction (**Supplementary Table 3**). The strongest
169 associations with PTSD_{Narrow} fell in the mental disorders category, including personality disorders
170 (*Antisocial/borderline personality disorder*, *Personality disorders*); mood disorders (*Mood disorders*,
171 *Depression*); suicide-related phecodes (*Suicidal ideation*, *Suicidal ideation or attempt*); substance use disorders

172 (*Substance addiction and disorders, Alcohol-related disorders*); and anxiety disorders (*Agoraphobia, social*
173 *phobia, and panic disorder, Anxiety disorder, Generalized anxiety disorder*). Beyond the mental disorders
174 category, PTSD_{Narrow} was associated with over 85% of phecodes in the infectious diseases category
175 (**Supplementary Table 3**). Phecodes with the largest odds ratios in association with PTSD_{Narrow} were *Anxiety*
176 *Disorders, Antisocial/borderline personality disorder, personality disorder, mood disorder, suicidal ideation,*
177 *suicide or self-inflicted injury, poisoning by psychotropic agents, and depression*.

178 Additionally, PTSD_{Narrow} showed strong associations with phecodes in the neurological and symptoms
179 categories pertaining to pain, including *Chronic pain, Back pain, Pain, and Nonspecific chest pain*. Several
180 genitourinary phecodes also emerged in association with PTSD_{Narrow}, for example, *Other symptoms/disorders of*
181 *the urinary system, Urinary tract infection, and Dysuria*.

182

183 **Broadly-defined PTSD shows strong associations with neuropsychiatric traits and respiratory, digestive,** 184 **genitourinary, and cardiovascular conditions**

185 PTSD_{Broad} was significantly associated with all phecodes in the mental disorders and infectious disease
186 categories and over 90% of phecodes in the respiratory, injuries & poisonings, symptoms and digestive categories
187 (**Supplementary Table 3**). Among the top 25% of significant phecodes, mental disorders, symptoms, and
188 respiratory PheCode categories were significantly enriched (**Supplementary Table 3**). The top phecode
189 associations with PTSD_{Broad} included mood disorders (*depression, suicidal ideation, anxiety, bipolar disorder*),
190 substance use disorders (*Substance addiction and disorders, alcohol related disorders alcoholism, tobacco use*
191 *disorder*), and other psychiatric disorders (*schizophrenia, ADHD*). The phecodes with the largest odds ratios in
192 association with PTSD_{Broad} were *antisocial/borderline personality* (OR=18.8 (18.61-19.00)), *personality disorder*
193 (OR=13.21 (13.07-13.34)), *suicidal ideation* (OR=9.4 (9.30-9.51)), and *anxiety disorders* (OR=9.37 (9.33-9.41)).

194 In addition to mental disorders, top associations with PTSD_{Broad} were related to a wide range of medical
195 phecode categories, including sleep (*insomnia, sleep disorders, malaise and fatigue*), pain (*back pain, chronic*
196 *pain, abdominal pain, pain, pain in joint*), respiratory system (*other symptoms of respiratory system, cough, acute*
197 *upper respiratory infections of multiple or unspecified sites, shortness of breath, pneumonia*), digestive system

198 *(nausea and vomiting, GERD, diseases of esophagus, esophagitis)*, genitourinary system (*urinary tract infection,*
199 *other symptoms disorders of the urinary system, dysuria*), cardiovascular system (*nonspecific chest pain, cardiac*
200 *dysrhythmias, hypertension, hypotension, arrhythmia, palpitations*), and asthma conditions.

201

202 **Clinical phenome associations were largely shared but showed some differences across PTSD definitions**

203 Significant phecode associations were largely shared between PTSD_{Narrow} and PTSD_{Broad} definitions,
204 especially the top-ranking associations (**Figure 2**). However, many more phecodes were significantly associated
205 with PTSD_{Broad} (1136/1367 tested) compared to PTSD_{Narrow} (807/1324), and 334 Bonferroni-significant phecodes
206 were associated with PTSD_{Broad} but not PTSD_{Narrow}. The strongest such associations included phecodes related to
207 skin (neoplasms of skin, dyschromia, actinic keratosis, other non-epithelial cancer of skin, dermatitis), lung
208 transplant and chronic pulmonary heart disease; however, these phecodes were not among the strongest hits for
209 PTSD_{Broad}. Only four phecodes were significantly associated following Bonferroni correction with PTSD_{Narrow} but
210 not PTSD_{Broad}. These included relatively uncommon genitourinary phecodes such as urethral hypermobility/ISD,
211 pelvic peritoneal adhesions, as well as amblyopia, and other disorders of middle ear and mastoid.

212

213 **Sex moderates associations between broadly-defined PTSD and several other phenotypes**

214 We conducted sex-stratified PTSD_{Narrow} and PTSD_{Broad} PheWAS, and meta-analyzed across sites
215 (**Supplementary figures 1-2; Supplementary Table 4**), and performed a PTSD-by-sex interaction test restricted to
216 only those phecodes with a Bonferroni-significant main effect within either sex (**Figure 3**). There were 16 phecodes
217 that were significantly different between males and females coded with PTSD_{Broad} after meta-analysis. Phenotypes
218 that were more common among male patients with PTSD_{Broad} included osteoporosis, respiratory failure,
219 subarachnoid and intracranial hemorrhage, and pulmonary heart disease. Phenotypes that were more common
220 among female patients with PTSD_{Broad} included urinary tract infection and other urinary symptoms, acute
221 pharyngitis, acute respiratory infections, and overweight, though directions of effect were not consistent between
222 sites for some phecodes. For PTSD_{Narrow}, other symptoms/disorder of the urinary system was the only phecode

223 with a significant sex interaction, driven by higher prevalence in males at MGB despite opposing associations
224 observed at the other two sites.

225

226 **Explanatory power of polygenic scores varies according to PTSD definition.**

227 We tested PGS associations with both PTSD_{Narrow} and PTSD_{Broad} (**Table 2**). PTSD PGS significantly
228 associated with both PTSD_{Narrow} (meta-analytic B=0.17, SE=0.02, p=5.6E-14, R² range= 0.08-0.29%; total cases:
229 11,075) and PTSD_{Broad} (meta-analytic B=0.07, SE=0.01, p=2.7E-11, R² range=0.08-0.43%; total cases: 2,116) in
230 EUR subsamples, although the proportion of variance explained (R²) was low. PGS were not significantly
231 associated among AA individuals for either PTSD_{Narrow} (B=0.06, SE=0.09, p= 0.30, R² range=0.0002-0.04%) or
232 PTSD_{Broad}(B=0.01, SE=0.09, p=0.53, R² range=0.006-0.32%), likely due to poor representation of African ancestry
233 alleles in existing PTSD GWAS.

234

235 Discussion

236 This study examined phenome-wide relationships between EHR-based PTSD and over 1300 medical
237 phecodes among over 123,000 participants across 3 health systems, including 14,899 and 3,026 individuals
238 meeting broad and narrow definitions for PTSD, respectively. We identified known and novel PTSD
239 comorbidities that replicated across multiple health systems and contextualized the relative strength of PTSD-
240 related associations across the medical phenome. Additionally, we identified several phenotypes for which males
241 and females exhibit differing relationships with PTSD. These results characterize a wide range of PTSD-related
242 diagnostic comorbidities in a health system setting and provide a useful catalog of phenotype-phenotype
243 relationships for interpreting future biobank-based genetic association studies of PTSD.

244

245 Contextualizing known and novel PTSD comorbidities

246 Our results build upon known psychiatric²⁹⁻³¹ and non-psychiatric PTSD comorbidities. Psychiatric
247 disorders were consistently identified as the strongest comorbidities for both broad and narrow PTSD definitions;
248 among non-psychiatric disorders, we observed a strong association of both PTSD definitions with pain
249 phenotypes, which encompass physical sensory components, as well as cognitive and emotional components³²⁻³⁶.
250 Given inflammatory/immune links to PTSD³⁷, we were surprised to find that autoimmune disorders such as
251 rheumatoid arthritis and multiple sclerosis were not significantly associated with PTSD. This suggests these
252 comorbidities may be less common on a health system scale, or that these comorbidities present with specific
253 PTSD subtypes (for example, those with a specific immune component or etiopathology) that are not well
254 represented or captured in our biobanks. Unexpectedly, we did not find significant associations between PTSD
255 and decreased libido³⁸. However, this phecode is relatively scarce in our biobanks (N=162-214), decreasing our
256 ability to detect associations. We identified novel associations of genitourinary phenotypes with PTSD, with a
257 particularly strong association with PTSD_{Broad}, with significance levels comparable to respiratory and
258 cardiovascular comorbidities. It is possible that these associations stem from shared risk factors, i.e., that sexual
259 assault or related traumatic experiences lead to both genitourinary and psychiatric outcomes³⁹, or are artefactual
260 associations resulting from cross-disorder correlations, where conditions that appear significant are not directly

261 associated with the exposure but rather linked to other diseases. It is also possible these associations reflect
262 “healthcare pleiotropy” – i.e., the association stems from an artifact of the clinical settings where traumatic
263 exposures are more commonly/routinely discussed (i.e., OB/GYN clinics).

264

265 **Sex differences in PTSD comorbidities**

266 Epidemiological evidence indicates that females exposed to traumatic events are at higher risk for
267 developing PTSD compared to trauma-exposed males. We identified several phenotypes for which associations
268 with PTSD_{Broad} differed between males and females. For females, obesity had a stronger association with PTSD
269 than males. This relationship has been previously reported for some studies of PTSD^{40,41} and other psychiatric
270 phenotypes⁴². We also found stronger association of urinary symptoms with PTSD in females. This may be due to
271 genito-urinary symptoms that occur at higher rates following exposure to abuse³⁸; for example, interstitial
272 cystitis/bladder pain syndrome⁴³, vulvodynia⁴⁴, and chronic pelvic pain^{45,46}, coupled with a greater prevalence of
273 sexual trauma among females^{17,47} or perhaps due to the clinical setting where trauma and genitourinary symptoms
274 are assessed. Respiratory failure, cranial hemorrhage, and pulmonary heart disease were more prevalent among
275 male PTSD_{Broad} cases. Together these results may reflect differential patterns of diagnosis of these disorders or
276 PTSD, differences in the care received between sexes (for example, in medical fields with sex specificity like
277 gynecology) or sex differences in PTSD pathology and the downstream system-wide consequences of having
278 PTSD.

279

280 **Scope of PTSD phenotyping and implications for genetic studies**

281 This study explored the role of phenotypic specificity in resolving comorbid phenotypes. A narrow
282 definition requiring multiple PTSD codes likely captures individuals with more severe and specific
283 symptomatology. In contrast, the broad definition, consisting of a single code inclusive of stress-related reactions,
284 may include individuals with a broader range of symptom severity. Psychiatric genetic studies increasingly tend
285 to include broader definitions which facilitate greater sample sizes, but at the potential cost of specificity¹². Both
286 PTSD definitions showed strikingly high levels of comorbidities. However, we found top PTSD_{Narrow} associations

287 were concentrated in mental disorders and pain-related symptoms, whereas PTSD_{Broad} associations were spread
288 across more phecode categories such as respiratory, genitourinary and circulatory conditions. Generally, the top
289 phecodes were consistent across both definitions, with the broader definition associated with 300 additional
290 phenotypes.

291 These association patterns have significant implications for our understanding of broad vs. narrow
292 definitions of psychiatric disorders and may shape future analytical and inclusion/exclusion criteria, as well as
293 how we should interpret associations specific to PTSD_{Broad}. The most significant of these were skin conditions
294 (dyschromia, actinic keratosis etc.), which may reflect racial differences in PTSD prevalence, trauma exposure, or
295 diagnostic rates¹⁵. To assess relevance for future studies, we consider each definition. If PTSD_{Broad} captures both
296 full PTSD and sub-threshold PTSD cases (or, if an accurate diagnosis is obtained using only one ICD code,
297 PTSD_{Broad} may capture primarily full PTSD cases), then we might conceptualize these associations as true PTSD
298 associations, discoverable only thanks to this increase in power. However, if the broad category involves
299 decreased diagnostic accuracy, PTSD_{Broad} may simply add ‘noise’ to the analysis, rather than identifying sub-
300 threshold or otherwise ‘missed’ cases, and these additional associations may not contribute meaningfully to our
301 understanding of PTSD and its comorbidities. At the genetic level, we observed that a PTSD PGS (trained on a
302 GWAS based on mainly studies of clinically ascertained PTSD²⁵) significantly associated with both PTSD_{Broad}
303 and PTSD_{Narrow} status, though more strongly PTSD_{Narrow} than PTSD_{Broad}. In the future, as sample sizes for PTSD
304 GWAS increase, focusing on more strictly defined cases may become more feasible and may lead to increased
305 predictive power of PGS.

306 Several factors suggest that the former, rather than latter, conceptualization is correct. First, addition of
307 truly random cases (i.e., introduction of ‘noise’) should reduce PheWAS discovery power⁴⁸ rather than identify
308 additional significant associations. Second, both PTSD_{Broad} and PTSD_{Narrow} have significant psychiatric
309 associations; it does not appear that one group is obviously more ‘accurately’ ascertained than the other. Third, we
310 note a primary difference between the two groups reflects frequency of diagnosis; a single ICD code for PTSD
311 does not necessarily imply an incorrect diagnosis, sub-clinical presentation, or less severe symptoms (this could
312 be examined through in-depth chart reviews in the future); rather, these patients may leave the medical system or be

313 referred elsewhere for treatment. In particular, we note that MSSM is associated with a VA, where veterans
314 experiencing combat-related PTSD may pursue PTSD care instead of the initial diagnostic site.

315

316

317 **Strengths and limitations**

318 Our study has several limitations to note when assessing and interpreting our results. First, while studying
319 the full clinical phenome using EHR is a strength of our study, our biobank-based patient populations may not be
320 fully representative of the general population. To some extent, we mitigate this concern by comparing effect sizes
321 and meta-analyzing⁴⁸ across three healthcare settings that represent distinct geographical areas (Boston, New
322 York, Nashville), with differing demographics and healthcare needs (e.g., the proportion of veterans seeking care
323 at these clinics differs significantly), and differing proportions of individuals with PTSD. In particular, one site
324 (MGB) has a much higher rate of PTSD diagnosis ($PTSD_{Narrow}$: 4.3% vs 1.9%, 1.7% at VUMC, MSSM,
325 respectively). Consequently, we observe some heterogeneity in effect size of associations; however, effect
326 directions are largely consistent across all three sites, which is highly unlikely to be due to chance (655
327 concordant across three sites vs. 169 discordant: binomial $p=4.84 \times 10^{-236}$; for codes present in two sites only: 340
328 concordant vs. 126 discordant, binomial $p=9.06 \times 10^{-24}$).

329 Given the majority of individuals are seeking care in a hospital setting for some symptom or condition,
330 EHR-based analyses likely underestimate the proportion of healthy individuals and will not identify sub-threshold
331 PTSD or those with well-managed PTSD receiving care in a different system. Our analysis also does not adjust
332 for utilization rates. Relatedly, individuals in our study may have uneven access to healthcare or to certain
333 specialists within a healthcare system: psychiatric or mental health services in particular may be unevenly
334 accessed due to differences in insurance coverage or stigma or immigration status. Even when healthcare is
335 accessed, patients may receive differing levels of care and stereotyping bias or institutionalized racism in
336 healthcare may lead to under- or over-diagnosis⁴⁸⁻⁵⁰. These issues may be particularly exacerbated in psychiatry,
337 where certain presentations of PTSD may be more readily diagnosed, potentially biasing our comorbidity results
338 towards that subtype of PTSD.

339 Another limitation is the lack of temporal resolution. Understanding whether these associated phecodes
340 occur prior to, or following, PTSD onset would ideally allow us to delineate associations into antecedents versus
341 potential consequences of PTSD diagnosis. However, this is difficult in practice: patients may report longstanding
342 existing diagnoses to a clinician upon enrollment at a new clinic, or receive correct diagnoses after long diagnostic
343 journeys. In the latter case, a patient may experience initial symptoms several years before an accurate diagnosis
344 of PTSD, such that other diagnoses received may either be comorbid with PTSD or represent inaccurate diagnoses
345 given to explain some of the PTSD symptoms (for example, MDD, or adjustment reaction disorder). Difficulty in
346 pinpointing disease onset precludes analysis of temporal relationships. Informed by this comprehensive map of
347 associations, studies should be repeated in longitudinal cohorts with detailed and repeated psychiatric
348 questionnaires that provide nuanced temporal resolution and can help shed light on the temporal nature of these
349 phenotype-phenotype relationships in PTSD. Further exploration of the genetic factors contributing to PTSD and
350 its comorbidities is also warranted.

351

352 **Conclusions and future directions**

353 This multi-site study investigated relationships between PTSD phenotypes and medical comorbidities
354 using data from over 123,000 patients across three major EHR-based healthcare systems. Our findings provide
355 insights into the diagnostic complexity of PTSD and its associations with the clinical phenome. By considering
356 both broad and narrow PTSD definitions, we comprehensively identified known and novel diagnostic
357 comorbidities, particularly in the domains of mental disorders, pain, respiratory, genitourinary, and cardiovascular
358 conditions. These associations were observed across multiple health systems, highlighting their generalizability.
359 Importantly, we observed sex differences in the associations between PTSD and certain medical phenotypes,
360 underscoring the need to consider sex-specific factors. Furthermore, our genetic analyses revealed significant
361 associations between polygenic scores derived from GWAS and both broad and narrow definitions of PTSD.
362 Future research should include longitudinal analyses to examine temporal relationships between PTSD and
363 medical comorbidities, providing insights into the directionality of these associations. Investigating sex-specific
364 factors, such as hormonal influences, trauma response differences, or care-seeking patterns, will enhance our

365 understanding of sex disparities in PTSD and associated medical conditions, while mechanistic studies could
366 explore underlying biological pathways and shared genetic factors contributing to the observed associations.
367 Overall, this study deepens our understanding of the diagnostic complexity of PTSD within EHRs and provides
368 insights for research towards integrated treatment approaches that address both PTSD diagnosis and its
369 comorbidities.
370

371 **Acknowledgements:**


372
373 This collaborative work was supported in part by the PsycheMERGE grant MH118233 (to JWS and LKD) and
374 administrative supplement to PGC PTSD R01 (R01MH106595). KWC was supported in part by funding from the
375 National Institute of Mental Health (K08MH127413) and a NARSAD Brain and Behavior Foundation Young
376 Investigator Award. EMH, JC and LMH acknowledge funding from NIMH (R01MH124839, R01MH118278)
377 and NIEHS (R01ES033630). LKD was supported by NIMH (R01MH118223); NHGRI and the Office of Research
378 on Women's Health (RM1HG009034).

379 MSSM: This work was supported in part through the computational resources and staff expertise provided by
380 Scientific Computing at the Icahn School of Medicine at Mount Sinai under award number S10OD018522 from
381 the Office of Research Infrastructure of the National Institutes of Health. This work was supported through the
382 resources and staff expertise provided by the Charles Bronfman Institute for Personalized Medicine and the
383 BioMe Biobank Program at the Icahn School of Medicine at Mount Sinai.

384 BioVU: The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's
385 BioVU which is supported by numerous sources: institutional funding, private agencies, and federal grants. These
386 include the NIH funded Shared Instrumentation Grant S10RR025141; and CTSA grants UL1TR002243,
387 UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include
388 U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711;
389 and additional funding sources listed at <https://victr.vumc.org/biovu-funding/>. This publication was supported by Grant
390 No. R01 HG011405, partially funded by the Office of Research on Women's Health, Office of the Director, NIH and the
391 National Human Genome Research Institute. Its contents are solely the responsibility of the authors and do not necessarily
392 represent the official views of the Office of Research on Women's Health or the National Human Genome Research Institute.

393
394 Disclosures: JWS is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity), and has
395 received grant support from Biogen, Inc. He is PI of a collaborative study of the genetics of depression and
396 bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no
397 payments.

398




399

400 **Figure 1.** A) PheWAS meta-analysis results for the narrow PTSD definition. B) PheWAS meta-analysis results
 401 for the broad PTSD definition. Phecodes are organized across the y-axis by their category, with the strength of
 402 association shown in the x-axis using $-\log_{10}p$. Red dashed line indicates the Bonferroni significance threshold.
 403 Bonferroni (**) and nominally significant (*) phecode category enrichments for the top 25% of phecode
 404 associations for PTSD_{Narrow} (mental disorders: $p < 0.0001$, symptoms: $p = 0.0001$, neurological: $p = 0.0019$,
 405 respiratory = 0.0081) and PTSD_{Broad} (mental disorders: $p < 0.0001$, symptoms: $p < 0.0001$, respiratory: $p = 0.0007$,
 406 neurological: $p = 0.0269$, musculoskeletal: $p = 0.0324$, endocrine/metabolic: $p = 0.0312$)

407


408



409

410 **Figure 2.** Top PheWAS hits are shared between narrowly and broadly defined PTSD. Phecodes ranked by p value
 411 are plotted for PTSD_{Broad} (x-axis) and PTSD_{Narrow} (y-axis). Phecodes with Bonferroni significant association with
 412 PTSD_{Narrow} (blue), PTSD_{Broad} (red), both (purple) or neither (gray) are indicated. Number of shared and distinct
 413 phecode associations for PTSD_{Narrow} and PTSD_{Broad} are shown in the inset.

414



415

416 **Figure 3** Phecodes with significant sex interaction with PTSD_{Narrow} (A) and PTSD_{Broad} (B) in at least one site or in
 417 meta-analysis across sites. Interaction term (PTSD * Sex) coefficients and standard errors are plotted for each site
 418 independently (MGB=blue, VUMC=green, MSSM=purple) and for a meta-analyzed interaction term coefficient
 419 (red). Bonferonni significant interaction terms are indicated with a filled circle. Positive interaction term indicates
 420 a higher prevalence in males and a negative interaction term indicates a higher prevalence in females.

421

422 **Tables**

		VUMC	MGB	MSSM	
Full Sample	N	73488	29885	19992	
	Current age (mean (SD); range)	59.66(19.53; 18-100)	61.55 (16.73; 22-105)	56.82 (16.51; 19-107)	
	Sex (N, % of females)	42106(57.3)	16413 (54.9%)	11970 (59.87%)	
	Ancestry	% European	62204(84.6%)	25787 (86.3%)	6554 (32.78%)
		% African American	11284(15.4%)	1562 (5.2%)	5222 (26.12%)
		% Hispanic	N/A	N/A	7130 (35.66%)
		% Admixed Americans	N/A	1797 (6.0%)	26 (0.13%)
		% East Asian	N/A	455 (1.5%)	596 (2.98%)
		% Native American	N/A	N/A	57 (0.29%)
% South Asian	N/A	284 (1.0%)	407 (2.04%)		
Number of ICD codes (mean, (SD); range)	258.3(375.2; 1-6937)	416 (540; 1-15722)	35.2(31.592; 1-232)		
PTSD Narrow cases	PTSD Narrow N	1399	1290	337	
	Current age (mean (SD); range)	47.67(16.65; 18.1-95.3)	52.07 (15.06; 23-94)	54.95 (11.54; 22-87)	
	Sex (N, % of females)	987 (70.6%)	914 (70.9%)	223(66.17%)	
	Ancestry	% European	1131(80.8%)	974 (75.5%)	51(15.13%)
		% African American	268(19.2%)	116 (9.0%)	97(28.78%)
		% Hispanic	N/A	N/A	185(54.9%)
		% Admixed Americans	N/A	189 (14.7%)	1(0.3%)
		% East Asian	N/A	7 (0.5%)	1(0.3%)
		% Native American	N/A	N/A	2(0.59%)
% South Asian	N/A	4 (0.3%)	N/A		
Number of ICD codes (mean, (SD); range)	524.9(648.8; 9-6937)	855 (859; 10-11073)	69.6 (36.51; 6-179)		
PTSD Broad cases	PTSD Broad N	6887	6616	1396	
	Current age (mean (SD); range)	55.14(18.5; 18.02-99.5)	59.90 (16.40; 23-101)	56.59 (15.66; 21-101)	
	Sex (N, % of females)	4557(66.2%)	4176 (63.1%)	1005(71.99%)	
	Ancestry	% European	5796(84.2%)	5285 (79.9%)	235(16.83%)
		% African American	1091(15.8%)	558 (8.4%)	461(33.02%)
		% Hispanic	N/A	N/A	665(47.64%)
		% Admixed Americans	N/A	670 (10.1%)	3(0.21%)
		% East Asian	N/A	65 (1.0%)	17(1.22%)
		% Native American	N/A	N/A	5(0.36%)
% South Asian	N/A	38 (0.6%)	10(0.72%)		
Number of ICD codes (mean, (SD); range)	538.2(621.1; 4-6933)	753 (751; 5-11073)	67.78 (37.43; 1-216)		

423
424

425 **Table 1.** Sample characteristics by site.

Ancestry Group	PTSD Definition	Site	PTSD ~ PRS + Age + Sex + PCs1:5			where PRS is scaled			Nagelkerke
			Beta	se	p	N case	N control	N total	
EUR	Narrow	MGB	0.1951	0.0344	0.00000008	936	19591	20527	0.425%
		VUMC	0.1500	0.0300	0.0000179	1131	56168	57299	0.230%
		BioMe	0.1117	0.1719	0.51576118	49	6307	6356	0.078%
		META-ANALYSIS	0.1685	0.0224	5.6E-14				
	Broad	MGB	0.0653	0.0161	0.0000476	5059	19765	25698	0.081%
		VUMC	0.0700	0.0140	0.0000018	5796	56408	62204	0.083%
		BioMe	0.1800	0.0824	0.0290112	220	6137	6357	0.291%
		META-ANALYSIS	0.0698	0.0105	2.7E-11				
AA	Narrow	MGB	-	-	-	-	-	-	-
		VUMC	0.0250	0.0700	0.7226	268	10158	10426	0.006%
		BioMe	-0.1723	0.1041	0.0980	96	5062	5158	0.315%
		META-ANALYSIS	-0.0364	0.0581	0.5305				
	Broad	MGB	-	-	-	-	-	-	-
		VUMC	0.0500	0.0370	0.1600	1091	10193	11284	0.038%
		BioMe	-0.0037	0.0496	0.9404	458	4703	5161	0.000%
		META-ANALYSIS	0.0308	0.0297	0.2990				

426
427

428 **Table 2.** PTSD polygenic score (PGS) Meta-analysis association statistics.

429

430 **Supplementary Tables**

431

1. Rank of top phecodes by site

432

2. Full summary statistics for PTSD PheWAS

433

3. PTSD PheWAS hits by PheCode category and Cross-category enrichment of PheCode categories for

434

PTSD PheWAS hits

435

4. Full summary statistics for sex-stratified PTSD PheWAS

436

437 **Supplementary Figures**

438

1. Male and female stratified PheWAS plot for PTSD Narrow

439

2. Male and female stratified PheWAS plot for PTSD Broad.

440

441 **References**

- 442 1. Sareen, J. *et al.* Physical and mental comorbidity, disability, and suicidal behavior associated with
443 posttraumatic stress disorder in a large community sample. *Psychosom. Med.* **69**, 242–248 (2007).
- 444 2. Flory, J. D. & Yehuda, R. Comorbidity between post-traumatic stress disorder and major depressive
445 disorder: alternative explanations and treatment considerations. *Dialogues Clin. Neurosci.* **17**, 141–
446 150 (2015).
- 447 3. Qassem, T., Aly-ElGabry, D., Alzarouni, A., Abdel-Aziz, K. & Arnone, D. Psychiatric Co-Morbidities
448 in Post-Traumatic Stress Disorder: Detailed Findings from the Adult Psychiatric Morbidity Survey in
449 the English Population. *Psychiatr. Q.* **92**, 321–330 (2021).
- 450 4. Pietrzak, R. H., Goldstein, R. B., Southwick, S. M. & Grant, B. F. Physical Health Conditions
451 Associated with Posttraumatic Stress Disorder in U.S. Older Adults: Results from Wave 2 of the
452 National Epidemiologic Survey on Alcohol and Related Conditions. *J. Am. Geriatr. Soc.* **60**, 296–
453 303 (2012).
- 454 5. Pacella, M. L., Hruska, B. & Delahanty, D. L. The physical health consequences of PTSD and
455 PTSD symptoms: a meta-analytic review. *J. Anxiety Disord.* **27**, 33–46 (2013).
- 456 6. Qureshi, S. U., Pyne, J. M., Magruder, K. M., Schulz, P. E. & Kunik, M. E. The link between post-
457 traumatic stress disorder and physical comorbidities: a systematic review. *Psychiatr. Q.* **80**, 87–97
458 (2009).
- 459 7. Johnston, K. J. A. & Huckins, L. M. Chronic Pain and Psychiatric Conditions. *Complex Psychiatry*
460 24–43 (2023) doi:10.1159/000527041.
- 461 8. Harrington, K. M. *et al.* Validation of an Electronic Medical Record-Based Algorithm for Identifying
462 Posttraumatic Stress Disorder in U.S. Veterans. *J. Trauma. Stress* **32**, 226–237 (2019).
- 463 9. Livingston, N. A. *et al.* Identifying Posttraumatic Stress Disorder and Disparity Among Transgender
464 Veterans Using Nationwide Veterans Health Administration Electronic Health Record Data. *LGBT*
465 *Health* **9**, 94–102 (2022).


- 466 10. Smoller, J. W. The use of electronic health records for psychiatric phenotyping and genomics. *Am.*
467 *J. Med. Genet. B Neuropsychiatr. Genet.* **177**, 601–612 (2018).
- 468 11. Stein, M. B. *et al.* Genome-wide association analyses of post-traumatic stress disorder and its
469 symptom subdomains in the Million Veteran Program. *Nat. Genet.* **53**, 174–184 (2021).
- 470 12. Cai, N. *et al.* Minimal phenotyping yields genome-wide association signals of low specificity for
471 major depression. *Nat. Genet.* **52**, 437–447 (2020).
- 472 13. Duncan, L. E. *et al.* Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia
473 and sex differences in heritability. *Mol. Psychiatry* **23**, 666–673 (2018).
- 474 14. Olf, M. Sex and gender differences in post-traumatic stress disorder: an update. *Eur. J.*
475 *Psychotraumatology* **8**, 1351204 (2017).
- 476 15. Marchese, S. & Huckins, L. M. Trauma Matters: Integrating Genetic and Environmental
477 Components of PTSD. *Adv. Genet.* 2200017 (2022) doi:10.1002/ggn2.202200017.
- 478 16. Kim, G. S. & Uddin, M. Sex-specific and shared expression profiles of vulnerability and resilience to
479 trauma in brain and blood. *Biol. Sex Differ.* **11**, 13 (2020).
- 480 17. Elliott, D. M., Mok, D. S. & Briere, J. Adult sexual assault: Prevalence, symptomatology, and sex
481 differences in the general population. *J. Trauma. Stress* **17**, 203–211 (2004).
- 482 18. Kucharska, J. Sex differences in the appraisal of traumatic events and psychopathology. *Psychol.*
483 *Trauma Theory Res. Pract. Policy* **9**, 575–582 (2017).
- 484 19. Mundy, S. S., Foss, S. L. W., Poulsen, S., Hjorthøj, C. & Carlsson, J. Sex differences in trauma
485 exposure and symptomatology in trauma-affected refugees. *Psychiatry Res.* **293**, 113445 (2020).
- 486 20. Muniz Carvalho, C. *et al.* Disentangling sex differences in the shared genetic architecture of
487 posttraumatic stress disorder, traumatic experiences, and social support with body size and
488 composition. *Neurobiol. Stress* **15**, 100400 (2021).
- 489 21. Kohane, I. S. *et al.* What Every Reader Should Know About Studies Using Electronic Health Record
490 Data but May Be Afraid to Ask. *J. Med. Internet Res.* **23**, e22219 (2021).

- 491 22. Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and
492 Initial Evaluation. *JMIR Med. Inform.* **7**, e14325 (2019).
- 493 23. Carroll, R. J., Bastarache, L. & Denny, J. C. R PheWAS: data analysis and plotting tools for
494 phenome-wide association studies in the R environment. *Bioinformatics* **30**, 2375–2376 (2014).
- 495 24. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide
496 association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 497 25. Nievergelt, C. M. *et al.* International meta-analysis of PTSD genome-wide association studies
498 identifies sex- and ancestry-specific genetic risk loci. *Nat. Commun.* **10**, 4558 (2019).
- 499 26. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat. Genet.* **54**,
500 573–580 (2022).
- 501 27. Nagelkerke, N. J. D. A note on a general definition of the coefficient of determination. *Biometrika*
502 **78**, 691–692 (1991).
- 503 28. Viechtbauer, W. Conducting Meta-Analyses in R with the **metafor** Package. *J. Stat. Softw.* **36**,
504 (2010).
- 505 29. Kang, B., Xu, H. & McConnell, E. S. Neurocognitive and psychiatric comorbidities of posttraumatic
506 stress disorder among older veterans: A systematic review. *Int. J. Geriatr. Psychiatry* **34**, 522–538
507 (2019).
- 508 30. Facer-Irwin, E., Karatzias, T., Bird, A., Blackwood, N. & MacManus, D. PTSD and complex PTSD in
509 sentenced male prisoners in the UK: prevalence, trauma antecedents, and psychiatric
510 comorbidities. *Psychol. Med.* **52**, 2794–2804 (2022).
- 511 31. Pietrzak, R. H., Goldstein, R. B., Southwick, S. M. & Grant, B. F. Psychiatric Comorbidity of Full and
512 Partial Posttraumatic Stress Disorder Among Older Adults in the United States: Results From Wave
513 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *Am. J. Geriatr.*
514 *Psychiatry* **20**, 380–390 (2012).


- 515 32. Asmundson, G. J., Coons, M. J., Taylor, S. & Katz, J. PTSD and the Experience of Pain: Research
516 and Clinical Implications of Shared Vulnerability and Mutual Maintenance Models. *Can. J.*
517 *Psychiatry* **47**, 930–937 (2002).
- 518 33. Sharp, T. J. & Harvey, A. G. Chronic pain and posttraumatic stress disorder: mutual maintenance?
519 *Clin. Psychol. Rev.* **21**, 857–877 (2001).
- 520 34. Brennstuhl, M.-J., Tarquinio, C. & Montel, S. Chronic Pain and PTSD: Evolving Views on Their
521 Comorbidity: Chronic Pain and PTSD: Evolving Views on Their Comorbidity. *Perspect. Psychiatr.*
522 *Care* **51**, 295–304 (2015).
- 523 35. Giordano, N. A. *et al.* Differential Pain Presentations Observed across Post-Traumatic Stress
524 Disorder Symptom Trajectories after Combat Injury. *Pain Med.* **22**, 2638–2647 (2021).
- 525 36. Gasperi, M., Afari, N., Goldberg, J., Suri, P. & Panizzon, M. S. Pain and Trauma: The Role of
526 Criterion A Trauma and Stressful Life Events in the Pain and PTSD Relationship. *J. Pain* **22**, 1506–
527 1517 (2021).
- 528 37. Katrinli, S., Oliveira, N. C. S., Felger, J. C., Michopoulos, V. & Smith, A. K. The role of the immune
529 system in posttraumatic stress disorder. *Transl. Psychiatry* **12**, 313 (2022).
- 530 38. Yehuda, R., Lehrner, A. m. y. & Rosenbaum, T. Y. PTSD and Sexual Dysfunction in Men and
531 Women. *J. Sex. Med.* **12**, 1107–1119 (2015).
- 532 39. Vézina-Gagnon, P. *et al.* Childhood sexual abuse, girls' genitourinary diseases, and psychiatric
533 comorbidity: A matched-cohort study. *Health Psychol.* **40**, 104–112 (2021).
- 534 40. Perkonig, A., Owash, T., Stein, M. B., Kirschbaum, C. & Wittchen, H.-U. Posttraumatic Stress
535 Disorder and Obesity. *Am. J. Prev. Med.* **36**, 1–8 (2009).
- 536 41. Tronieri, J. S., Wurst, C. M., Pearl, R. L. & Allison, K. C. Sex Differences in Obesity and Mental
537 Health. *Curr. Psychiatry Rep.* **19**, 29 (2017).
- 538 42. Lopresti, A. L. & Drummond, P. D. Obesity and psychiatric disorders: Commonalities in
539 dysregulated biological pathways and their implications for treatment. *Prog.*
540 *Neuropsychopharmacol. Biol. Psychiatry* **45**, 92–99 (2013).

- 541 43. McKernan, L. C. *et al.* Posttraumatic stress disorder in interstitial cystitis/bladder pain syndrome:
542 Relationship to patient phenotype and clinical practice implications. *Neurourol. Urodyn.* **38**, 353–
543 362 (2019).
- 544 44. Iglesias-Rios, L., Harlow, S. D. & Reed, B. D. Depression and Posttraumatic Stress Disorder
545 Among Women with Vulvodynia: Evidence from the Population-Based Woman to Woman Health
546 Study. *J. Womens Health* **24**, 557–562 (2015).
- 547 45. Lamvu, G., Carrillo, J., Ouyang, C. & Rapkin, A. Chronic Pelvic Pain in Women: A Review. *JAMA*
548 **325**, 2381 (2021).
- 549 46. Meltzer-Brody, S. *et al.* Trauma and Posttraumatic Stress Disorder in Women With Chronic Pelvic
550 Pain. *Obstet. Gynecol.* **109**, 902–908 (2007).
- 551 47. Tolin, D. F. & Foa, E. B. Sex differences in trauma and posttraumatic stress disorder: A quantitative
552 review of 25 years of research. *Psychol. Bull.* **132**, 959–992 (2006).
- 553 48. Dueñas, H. R., Seah, C., Johnson, J. S. & Huckins, L. M. Implicit bias of encoded variables:
554 frameworks for addressing structured bias in EHR–GWAS data. *Hum. Mol. Genet.* **29**, R33–R41
555 (2020).
- 556 49. Huckins, L. M. Thoughtful Phenotype Definitions Empower Participants and Power Studies.
557 *Complex Psychiatry* **8**, 57–62 (2022).
- 558 50. Huckins, L. M. *et al.* What next for eating disorder genetics? Replacing myths with facts to sharpen
559 our understanding. *Mol. Psychiatry* **27**, 3929–3938 (2022).
- 560


A



B




Narrow PTSD PheWAS pvalue rank




A

Narrow PTSD




B


Broad PTSD




A. Females - Narrow PTSD



B. Males - Narrow PTSD



A. Females - Broad PTSD



B. Males - Broad PTSD

